Pulmonary vein antrum isolation in patients with paroxysmal atrial fibrillation: more than a decade of follow-up.Atrial fibrillation (AFib) is the most common type of abnormal heart rhythm.Although this agent has no direct effect on platelet aggregation, it does indirectly inhibit platelet aggregation induced by thrombin.

It inhibits free and clot-bound Factor Xa, and prothrombinase activity.The number of new cases each year of atrial fibrillation increases with age.Atrial Fibrillation drugs are grouped into the following classes based on how they work.Connolly SJ, Pogue J, Hart RG, et al, for the ACTIVE Investigators.Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis.Repeat ablation wins out over antiarrhythmic agents for recurrent paroxysmal.Quinidine, procainamide, and disopyramide are class IA antiarrhythmic agents used to maintain sinus rhythm.A short half-life of 8 min allows for titration to the desired effect and quick discontinuation if needed.

If successful, rhythm control can eliminate or delay the need for long-term anticoagulation with warfarin in some patients.Steinberg BA, Kim S, Piccini JP, et al, for the ORBIT-AF Investigators and Patients.

Cryoablation, a new treatment for afib - St. George News

Transcranial measurement of cerebral microembolic signals during pulmonary vein isolation: a comparison of two ablation techniques.It prolongs repolarization by increasing the slow inward sodium current and by blocking the delayed rectifier current with rapid onset.The following algorithm incorporates clinical trial data on the safety and efficacy of antiarrhythmic agents.Results from the Rate Control Versus Electrical Cardioversion (RACE) Study.Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis.Emergency Medicine Cases (EM Cases) is a free online medical education podcast, medical blog and website dedicated to providing online emergency medicine education.Doctors at Heart Hospital in Plano have combined two technologies in a new approach to treating atrial fibrillation.

The latest in Atrial Fibrillation news, help, and current heart related treatments.Hagens VE, Ranchor AV, Van Sonderen E, et al, for the RACE Study Group.

New to this site and new with AFib - HealthUnlocked

Laser, video technology combine in new atrial fibrillation

Atrial fibrillation can be worrisome, but in many cases, the biggest risks can be reduced with blood thinning medication.FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm.Anticoagulants are used to prevent thromboembolic complications.During intravenous administration, carefully monitor blood pressure, heart rate, and ECG.The goals of medical therapy for patients with atrial fibrillation (AF) are to maintain sinus rhythm, avoid the risk of complications (eg, stroke), and minimize symptoms.Atenolol selectively blocks beta-1 receptors, with little or no effect on beta-2 types.Some patients demonstrate a slowing in the atrial rate and an increase in AV conduction, with rapid ventricular rates, when treated with class IA agents alone.Lowes R. FDA okays Kcentra to reverse anticoagulation, stop bleeding.

As with all class IA agents, QRS and QTc prolongation are the main ECG manifestations.

What medicines can cause atrial fibrillation? - Atrial

DECAAF: targeting MRI-identified fibrosis during ablation improves outcomes.

Clot Treatment - Blood Clots

Pacing in prevention of atrial fibrillation: the PIPAF studies.CHADS2 Score for Stroke Risk Assessment in Atrial Fibrillation.

Although the proarrhythmic effect of these drugs extends into the maintenance phase, a monitored inpatient setting is generally recommended for drug initiation, especially for those patients with structural heart disease or substantial comorbidities.Oral anticoagulant (warfarin, dabigatran, apixaban, or rivaroxaban) individualized based on patient risk factors (particularly risk for intracranial hemorrhage), cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics.

Factor Xa inhibitor indicated reduce risk of stroke and systemic embolism with nonvalvular atrial fibrillation.Diltiazem is the drug of choice for rate control in many cases.A new guideline for atrial fibrillation (AF) was released on Friday by the American Heart Association, the American College of Cardiology, and the Heart.Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.Two-fold increases in 2 other endpoints, stroke and hospitalization for heart failure, were also noted when compared with placebo.Study Identifies Dangerous Combination of AFib Drugs When taken together, amiodarone and warfarin can increase stroke risk, finds study.

Frequency of toxicity with chemical conversion of atrial fibrillation with dofetilide.Ali A Sovari, MD, FACP is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Heart Association, American Medical Association, American Physiological Society, and Heart Rhythm Society.Schmidt et al found that the use of non-aspirin nonsteroidal anti-inflammatory agents (NSAIDs) is associated with an increased risk of AF or flutter, suggesting a need to add this caution when prescribing this course of medication.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM.Dr John Mandrola summarizes and gives his take on the new treatment guidelines for atrial fibrillation.

Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.More than 3 million Americans have atrial fibrillation, a problem with the electrical system of the heart that.Reduced doses of direct thrombin or factor Xa inhibitors may be considered (eg, dabigatran, rivaroxaban, apixaban), but safety and efficacy have not been established.Hand L. FDA delays approval decision for factor Xa inhibitor antidote.